欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
PC-9人肺腺癌细胞[套餐促销]
英文名:PC-9
货号:ZQ0487
价格:¥1600.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

PC-9人肺腺癌细胞[套餐促销]

¥1600.00
+

PC-9人肺癌细胞专用培养基

¥350.00 ¥480.00

配套完培,组合使用,省时省力!

=

细胞套餐惊爆价

¥1950 ¥2080.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

PC-9人肺腺癌细胞

货号

ZQ0487

产品介绍

PC-9是一种人肺腺癌细胞系,最初来源于一位45岁男性的肺腺癌组织。这些细胞最初被命名为PC-14,后来通过STR DNA分析发现与PC-9细胞系相同,因此更名为PC-9。PC-9 是源自人肺腺癌(分化型)的细胞系。PC-9细胞系在非小细胞肺癌(NSCLC)的研究中非常重要,尤其是在研究肺癌细胞的生物学特性、药物敏感性以及分子机制方面。PC-9细胞系是研究肺癌的重要工具,为科学家们提供了一个模型系统,用于研究疾病的进展和开发新的治疗方法。

种属

性别/年龄

男性/45岁

组织

疾病

腺癌

细胞类型

肿瘤细胞 

形态学

圆形和纺锤形混合

生长方式

贴壁

倍增时间

大约96~144小时

培养基和添加剂

DMEM高糖(中乔新舟 货号:ZQ-100)+10%胎牛血清(中乔新舟  货号:ZQ500-TS+1%双抗(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0487

生物安全等级

BSL-1

STR位点信息

Amelogenin:X
CSF1PO: 11
D1S1656:15
D2S441: 11
D2S1338:19,20
D3S1358:16
D5S818: 11
D7S820: 10,11
D8S1179:11,15
D10S1248:13
D12S391:18
D13S317:8
D16S539:9
D18S51: 15
D19S433:13,15.2
D21S11: 30
D22S1045:16,17
FGA:23
Penta D: 13
Penta E: 11
TH01:7
TPOX:11
vWA:17

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

BCRJ; 0331 RCB; RCB4455

供应限制

仅供科研使用


货号

ZQ0487

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


1、论文标题: CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells
DOI: 10.1016/j.omto.2021.07.003
发表时间: 2021-07-16
期刊: Molecular Therapy-Oncolytics
影响因子: 7.2
货号: ZQ0487
产品名称: PC-9 cells

原文链接: https://www.sciencedirect.com/science/article/pii/S2372770521001005


2、论文标题: The functional landscape of Golgi membrane protein 1 (GOLM1) phosphoproteome reveal GOLM1 regulating P53 that promotes malignancy
DOI: 10.1038/s41420-021-00422-2
发表时间: 2021-03-01
期刊: Cell Death Discovery
影响因子: 5.241
货号: ZQ0487
产品名称: PC9 cell
原文链接: https://www.nature.com/articles/s41420-021-00422-2


3、论文标题: Comprehensive analysis of an immune infiltrate-related competitive endogenous RNA network reveals potential prognostic biomarkers for non-small cell lung cancer
DOI: 10.1371/journal.pone.0260720
发表时间: 2021-12-02
期刊: PLoS One
影响因子: 3.24
货号: ZQ0487
产品名称: PC-9 cells
原文链接: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0260720


4、PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)


5、PubMed=22313637; DOI=10.4161/cbt.19238
Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E.
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Cancer Biol. Ther. 13:369-378(2012)


6、PubMed=23733853; DOI=10.1101/gr.152322.112
Jia P.-L., Jin H.-L., Meador C.B., Xia J.-F., Ohashi K., Liu L., Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z.-M., Pao W.
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
Genome Res. 23:1434-1445(2013)


7、PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)


8、PubMed=26202522; DOI=10.1021/acs.jproteome.5b00477
Kitata R.B., Dimayacyac-Esleta B.R.T., Choong W.-K., Tsai C.-F., Lin T.-D., Tsou C.-C., Weng S.-H., Chen Y.-J., Yang P.-C., Arco S.D., Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.
Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry.
J. Proteome Res. 14:3658-3669(2015)


9、PubMed=26554430; DOI=10.1021/acs.analchem.5b03639
Dimayacyac-Esleta B.R.T., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J.
Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.
Anal. Chem. 87:12016-12023(2015)


10、PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)


11、PubMed=28290473; DOI=10.1038/srep44021
Wang Y.-T., Pan S.-H., Tsai C.-F., Kuo T.-C., Hsu Y.-L., Yen H.-Y., Choong W.-K., Wu H.-Y., Liao Y.-C., Hong T.-M., Sung T.-Y., Yang P.-C., Chen Y.-J.
Phosphoproteomics reveals HMGA1, a CK2 substrate, as a drug-resistant target in non-small cell lung cancer.
Sci. Rep. 7:44021-44021(2017)


12、PubMed=29681454; DOI=10.1016/j.cell.2018.03.028
McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)


13、PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


14、PubMed=34320349; DOI=10.1016/j.celrep.2021.109441
Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K., Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L., Leite de Oliveira R., Wessels L.F.A., Bernards R.
The cancer SENESCopedia: a delineation of cancer cell senescence.
Cell Rep. 36:109441.1-109441.22(2021)


公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号